Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.
DAVIS, Calif.--(BUSINESS WIRE)--The non-profit consortium is developing publicly accessible advanced AI-based drug discovery software tools.
A blood test that checks for an abnormal protein could detect 90% of Alzheimer's cases. Eli Lilly recently obtained approval for an early Alzheimer's treatment, Kisunla.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to
Biogen Inc. (BIIB) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $4 per share. This compares to earnings of $4.02 per share a year ago.
Biogen Inc.'s stock BIIB rose 1.8% in premarket trading on Thursday after the drug aker boosted its outlook for its adjusted 2024 profit and topped Wall Street's second-quarter profit expectations. Th
Biogen reported second-quarter earnings and revenye that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, Leqem
Biogen lifted its full-year earnings forecast on Thursday, as the launch of new treatments such as rare disease drug Skyclarys is expected to make up for a market-share loss of its older multiple scle
Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF). The first stage of the pivotal IDE PI
The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data prese
51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE